Archive · Business Recorder
Citi Pharma’s acquisition of Pakheim clears scrutiny in five drug markets
ISLAMABAD: Citi Pharma Limited’s acquisition of Pakheim International Pharma (Pvt) Limited has cleared scrutiny in five medicine markets, with the Competition Commission of Pakistan (CCP) finding limited overlaps and no substantial threat to competition. CCP’s Phase-I order authorises the purchase of Pakheim’s entire shareholding under a share purchase agreement signed on May 6, 2026. Pakheim would become a wholly owned subsidiary of Citi Pharma upon completion. The detailed order identifies four individual sellers: Mossadaq Farhan, Arif Ahmed Khawaja, Muhammad Mustafizur Rehman and Muhammad I...
ZAZTEK archives the headline, summary and publication date so the story stays findable. The full article remains the publisher's. Read it at Business Recorder →